Answers are grounded in this paper and cite their sources.
To assess the effect of nasal foralumab, a fully-human anti-CD3 monoclonal-antibody on microglial activation in non-active secondary progressive multiple sclerosis (na-SPMS) with PIRA (progression independent of relapses).
No takes yet. Share an insight, caveat, or question.
Singhal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: